Pipeline

ENABLING BROAD APPLICATIONS FOR RNA TREATMENTS

Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas. Our pipeline achieves initial clinical proof of concept in infectious disease, demonstrating a best-in-class technology, advances a first-in-class oncology candidate to IND, and demonstrates the potential of the technology with two candidate selections in major therapeutic areas with clear preclinical inflection points.

A simple blue line-drawing pattern of human silhouettes arranged in three rows.
A simple blue line-drawing pattern of human silhouettes arranged in three rows.

Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas. Our pipeline achieves initial clinical proof of concept in infectious disease, demonstrating a best-in-class technology, advances a first-in-class oncology candidate to IND, and demonstrates the potential of the technology with two candidate selections in major therapeutic areas with clear preclinical inflection points.

Program
Indication & Mechanism
Discovery
Preclinical
Clinical – Phase 1
Clinical – Phase 2
Infectious Disease

srRNA technology allows us to rapidly develop effective, low-dose vaccines for complex infectious disease targets.

LEARN MORE ABOUT COMPLEX INFECTIOUS DISEASe
RBI-4000
Rabies Viral Glycoprotein
CLINICAL – PHASE 1
RBI-5000
Complex Infectious Disease Viral Glycoproteins
DISCOVERY
Oncology

Targeted cancer therapy often results in predictable mutations that lead to drug resistance. Precision immuno-oncology is our approach to treating cancer by preventing clinical resistance from developing. Our srRNAs educate the immune system to recognize and remove common mutations, extending the time that people with cancer may benefit from a targeted therapy.

LEARN MORE ABOUT PRECISION IMMUNO-ONCOLOGy
RBI-1000
Breast Cancer Endocrine Therapy Resistance
IND-enabling
RBI-3000
Lung Cancer Targeted Therapy Resistance
DISCOVERy
Immunology

Autoimmune diseases are often driven by the overexpression of inflammatory molecules. Current approaches struggle to quell this over-activity. Our pipeline includes srRNA-encoded molecules that halt the pathways that drive inflammatory and autoimmune diseases by targeting downstream mediators of the inflammasome.

RBI-8000
Autoimmunity Inflammasome
DISCOVERY
Clinical trial information
Replicate is currently studying RBI-4000 in a Phase 1 clinical trial to evaluate clinical proof of concept, safety, and tolerability in humans. To find out more about the trial and eligibility, visit:
A cut-out image of two scientists wearing goggles, white lab coats, and black gloves. One scientist is pipetting liquid into a tray while the other looks on. They are superimposed on a light blue wave background with a bright light trail. A cut-out image of two scientists wearing goggles, white lab coats, and black gloves. One scientist is pipetting liquid into a tray while the other looks on. They are superimposed on a light blue wave background with a bright light trail.